共 29 条
- [1] Wu AM(2005)Arming antibodies: prospects and challenges for immunoconjugates Nat Biotechnol 23 1137-1146
- [2] Senter PD(2008)Antibody-drug conjugates for cancer therapy Cancer J 14 154-169
- [3] Carter PJ(2006)Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates J Biol Chem 281 10540-10547
- [4] Senter PD(2003)cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity Blood 102 1458-1465
- [5] Sutherland MS(2005)International conference on harmonization; guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; availability Notice Fed Regist 70 61134-61135
- [6] Sanderson RJ(2007)Revised response criteria for malignant lymphoma J Clin Oncol 25 579-586
- [7] Gordon KA(2008)Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review J Clin Pharmacol 48 13-18
- [8] Francisco JA(2001)Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling Drug Saf 24 323-351
- [9] Cerveny CG(2010)Interval shortening: potential harbinger of proarrhythmia and regulatory perspectives Br J Pharmacol 159 58-69
- [10] Meyer DL(2012)Brentuximab Vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: results of a phase 2 study J Clin Oncol 30 2190-2196